Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy

Description

Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits.

Conditions

Eosinophilic Esophagitis (EoE)

Talk to us

Study Overview

On this page

Study Details

Study overview

Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits.

Monitoring Eosinophilic Esophagitis During Food Oral Immunotherapy Using Esophageal String Test

Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy

Condition
Eosinophilic Esophagitis (EoE)
Intervention / Treatment

-

Contacts and Locations

Philadelphia

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female, aged 7 to 18 years old, inclusive
  • * Have a history of Immunoglobulin (IgE)-mediated food allergy
  • * Undergoing oral immunotherapy (OIT) for food allergies at CHOP°
  • * Able \& willing to swallow the esophageal capsule
  • * Parental/guardian permission (informed consent) and if appropriate, child assent.
  • * Willing to comply with all study procedures and be available for the duration of the study.
  • * Known or expected need for MRI imaging during the study period
  • * Known connective tissue disease
  • * Known eosinophilic disorder including any eosinophilic gastrointestinal disorder and hypereosinophilic disorder
  • * Past history of caustic ingestion or other esophageal injury
  • * History of esophageal surgery or dilation (i.e.: tracheoesophageal fistula repair)
  • * History of gastrointestinal motility disorder including esophageal achalasia
  • * History of inflammatory bowel disease
  • * Unwilling or unable to swallow the EST
  • * Oral or intravenous steroids in the preceding 60 days (not including swallowed topical fluticasone, budesonide, etc.)
  • * Participation in a clinical study that may interfere with participation in this study
  • * Pregnant or lactating females
  • * Limited English proficiency
  • * Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

Ages Eligible for Study

7 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital of Philadelphia,

Jonathan M Spergel, MD, PhD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Study Record Dates

2026-10-01